Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...

Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc....

Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol Journal of Ocular Pharmacology and Therapeutics Peer-Reviewed Journal Publishes NB2222 Ocular Bioavailability Data LONG BEACH, CA, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald...

Emerald Bioscience Secures “All Fields” Licenses for Cannabinoid Derivatives Developed by University of Mississippi Licenses Permit Emerald to Develop THC-Prodrug and CBD-Analog for Any Therapeutic Indication by Any Route of Administration for Human and Veterinary Use LONG BEACH, CA, May 29, 2019 (GLOBE...

Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference LONG BEACH, CA, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...